Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 95

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 95
---
 reporting obligations and oversight if we become subject to a corporate integrity agreement or
other agreement to resolve allegations of non-compliance with these laws. Further, if any of the physicians or other healthcare providers
or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant
criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Any action for violation
of these laws, even if successfully defended, could cause a pharmaceutical manufacturer to incur significant legal expenses and divert
management’s attention from the operation of the business. Therefore, even if we are successful in defending against any such actions
that may be brought against us, our business may be impaired. Prohibitions or restrictions on sales or withdrawal of future marketed products
could materially affect business in an adverse way.

| 46 |

Risks Related to Ownership of Our Securities and Our Status as a U.S. Listed Company

If we cannot meet NASDAQ’s continued listing requirements, NASDAQ may delist our Depositary Shares, which could have an adverse impact on the liquidity and market price of our Depositary Shares.

Our Depositary Shares are currently listed on the NASDAQ Capital Market. We are required to meet certain qualitative and financial tests to maintain the listing of the Depositary Shares on the NASDAQ Capital Market. On August 27, 2024, we received aLetter from the Listing
Qualifications Department of NASDAQ, notifying us of the Staff’s determination to delist our securities from the NASDAQ Capital
Market because our securities had not complied with the Minimum Bid Price Requirement. Normally, a company would be afforded a 180-calendar
day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to NASDAQ Listing Rule 5810(c)(3)(A)(iv),
we were not eligible for any compliance period specified in Rule 5810(c)(3)(A) because we effected reverse stock splits over the prior
two-year period with a cumulative ratio of 250 shares or more to one. Accordingly, and as described in the Letter, unless we timely requested
a hearing before the Panel, our securities would be subject to suspension/delisting. We requested a hearing, which automatically stayed
any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following
the hearing.

On October 14, 2024, the Panel
granted our request for an extension of time to demonstrate compliance with the Minimum Bid Price